LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 5 of total 5

Search options

  1. Article ; Online: Stereotactic body radiotherapy plus rucosopasem in locally advanced or borderline resectable pancreatic cancer: GRECO-2 phase II study design.

    Hoffe, Sarah E / Aguilera, Todd A / Parikh, Parag J / Ghaly, Maged M / Herman, Joseph M / Caster, Joseph M / Kim, Dae Won / Costello, James / Malafa, Mokenge P / Moser, Elizabeth C / Kennedy, Eugene P / Terry, Kara / Kurman, Michael

    Future oncology (London, England)

    2024  Volume 20, Issue 8, Page(s) 437–446

    Abstract: Ablative doses of stereotactic body radiotherapy (SBRT) may improve pancreatic cancer outcomes but may carry greater potential for gastrointestinal toxicity. Rucosopasem, an investigational selective dismutase mimetic that converts superoxide to hydrogen ...

    Abstract Ablative doses of stereotactic body radiotherapy (SBRT) may improve pancreatic cancer outcomes but may carry greater potential for gastrointestinal toxicity. Rucosopasem, an investigational selective dismutase mimetic that converts superoxide to hydrogen peroxide, can potentially increase tumor control of SBRT without compromising safety. GRECO-2 is a phase II, multicenter, randomized, double-blind, placebo-controlled trial of rucosopasem in combination with SBRT in locally advanced or borderline resectable pancreatic cancer. Patients will be randomized to rucosopasem 100 mg or placebo via intravenous infusion over 15 min, before each SBRT fraction (5 × 10 Gy). The primary end point is overall survival. Secondary end points include progression-free survival, locoregional control, time to metastasis, surgical resection rate, best overall response, in-field local response and acute and long-term toxicity.
    MeSH term(s) Humans ; Adenocarcinoma ; Clinical Trials, Phase II as Topic ; Dose Fractionation, Radiation ; Multicenter Studies as Topic ; Pancreatic Neoplasms/diagnosis ; Pancreatic Neoplasms/radiotherapy ; Pancreatic Neoplasms/drug therapy ; Radiosurgery/adverse effects ; Randomized Controlled Trials as Topic
    Language English
    Publishing date 2024-01-24
    Publishing country England
    Document type Clinical Trial Protocol ; Journal Article
    ZDB-ID 2274956-1
    ISSN 1744-8301 ; 1479-6694
    ISSN (online) 1744-8301
    ISSN 1479-6694
    DOI 10.2217/fon-2022-1219
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6478: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: A phase 1 study of the irreversible FLT3 inhibitor FF-10101 in relapsed or refractory acute myeloid leukemia.

    Levis, Mark J / Perl, Alexander E / Schiller, Gary J / Fathi, Amir T / Roboz, Gail J / Wang, Eunice S / Altman, Jessica K / Rajkhowa, Trivikram / Ando, Makoto / Suzuki, Takeaki / Subach, Ruth Ann / Maier, Gary / Madden, Timothy / Johansen, Mary / Cheung, Kin / Kurman, Michael / Smith, Catherine C

    Blood advances

    2024  

    Abstract: FLT3 tyrosine kinase inhibitors (TKIs) have clinical efficacy for patients with FLT3-mutated AML (acute myeloid leukemia), but their impact is limited by resistance in the setting of monotherapy and by tolerability problems when used in combination ... ...

    Abstract FLT3 tyrosine kinase inhibitors (TKIs) have clinical efficacy for patients with FLT3-mutated AML (acute myeloid leukemia), but their impact is limited by resistance in the setting of monotherapy and by tolerability problems when used in combination therapies. FF-10101 is a novel compound that covalently binds to a cysteine residue near the active site of FLT3, irreversibly inhibiting receptor signaling. It is effective against most FLT3 activating mutations, and unlike other inhibitors is minimally vulnerable to resistance induced by FLT3 ligand (FL). We conducted a phase 1 dose escalation study of oral FF-10101 (NCT03194685) in patients with relapsed and/or refractory AML, the majority of whom harbored FLT3-activating mutations and/or had prior exposure to FLT3 inhibitors. Fifty-four participants enrolled in cohorts ranging from 10 to 225 mg per day and 50 to 100 mg twice daily (BID). The dose limiting toxicities (DLT) were diarrhea and QT prolongation. Among 40 response-evaluable participants, the composite complete response rate was 10%, and the overall response rate (including partial responses) was 12.5%, including patients who had progressed on gilteritinib. 56% of participants had prior exposure to FLT3 inhibitors. The recommended phase 2 dose (RP2D) was 75 mg BID. FF-10101 potentially represents a next-generation advance in the management of FLT3-mutated AML.
    Language English
    Publishing date 2024-03-19
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2915908-8
    ISSN 2473-9537 ; 2473-9529
    ISSN (online) 2473-9537
    ISSN 2473-9529
    DOI 10.1182/bloodadvances.2023010619
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 7153: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Results of a Phase 1/2a dose-escalation study of FF-10501-01, an IMPDH inhibitor, in patients with acute myeloid leukemia or myelodysplastic syndromes.

    Garcia-Manero, Guillermo / Pemmaraju, Naveen / Alvarado, Yesid / Naqvi, Kiran / Ravandi, Farhad / Jabbour, Elias / De Lumpa, Ricardo / Kantarjian, Hagop / Advani, Anjali / Mukherjee, Sudipto / Gerds, Aaron / Carraway, Hetty E / Nazha, Aziz / Iwamura, Hiroyuki / Murase, Motohiko / Bavisotto, Linda / Kurman, Michael / Maier, Gary / Johansen, Mary /
    Sekeres, Mikkael A

    Leukemia & lymphoma

    2020  Volume 61, Issue 8, Page(s) 1943–1953

    Abstract: FF-10501-01 potently inhibits inosine-5-monophosphate dehydrogenase (IMPDH), inducing anti-proliferative and pro-apoptotic effects in acute myeloid leukemia (AML) human cell lines resistant to hypomethylating agents. In this Phase 1/2a study, Phase 1 ... ...

    Abstract FF-10501-01 potently inhibits inosine-5-monophosphate dehydrogenase (IMPDH), inducing anti-proliferative and pro-apoptotic effects in acute myeloid leukemia (AML) human cell lines resistant to hypomethylating agents. In this Phase 1/2a study, Phase 1 enrolled 38 patients with relapsed/refractory AML (
    MeSH term(s) Enzyme Inhibitors/adverse effects ; Humans ; IMP Dehydrogenase ; Leukemia, Myeloid, Acute/drug therapy ; Myelodysplastic Syndromes/drug therapy
    Chemical Substances Enzyme Inhibitors ; IMP Dehydrogenase (EC 1.1.1.205)
    Language English
    Publishing date 2020-04-07
    Publishing country United States
    Document type Clinical Trial, Phase I ; Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 1042374-6
    ISSN 1029-2403 ; 1042-8194
    ISSN (online) 1029-2403
    ISSN 1042-8194
    DOI 10.1080/10428194.2020.1747065
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2997: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Mogamulizumab

    Phillips, Adrienne A / Fields, Paul A / Hermine, Olivier / Ramos, Juan C / Beltran, Brady E / Pereira, Juliana / Wandroo, Farooq / Feldman, Tatyana / Taylor, Graham P / Sawas, Ahmed / Humphrey, Jeffrey / Kurman, Michael / Moriya, Junji / Dwyer, Karen / Leoni, Mollie / Conlon, Kevin / Cook, Lucy / Gonsky, Jason / Horwitz, Steven M

    Haematologica

    2018  Volume 104, Issue 5, Page(s) 993–1003

    Abstract: Mogamulizumab, a humanized defucosylated anti-C-C chemokine receptor 4 monoclonal antibody, has been approved in Japan for the treatment of C-C chemokine receptor 4-positive adult T-cell leukemia/lymphoma (ATL). This phase II study evaluated efficacy and ...

    Abstract Mogamulizumab, a humanized defucosylated anti-C-C chemokine receptor 4 monoclonal antibody, has been approved in Japan for the treatment of C-C chemokine receptor 4-positive adult T-cell leukemia/lymphoma (ATL). This phase II study evaluated efficacy and safety of mogamulizumab in ATL patients with acute, lymphoma, and chronic subtypes with relapsed/refractory, aggressive disease in the US, Europe, and Latin America. With stratification by subtype, patients were randomized 2:1 to intravenous mogamulizumab 1.0 mg/kg once weekly for 4 weeks and biweekly thereafter (n=47) or investigator's choice of chemotherapy (n=24). The primary end point was confirmed overall response rate (cORR) confirmed on a subsequent assessment at 8 weeks by blinded independent review. ORR was 11% (95%CI: 4-23%) and 0% (95%CI: 0-14%) in the mogamulizumab and chemotherapy arms, respectively. Best response was 28% and 8% in the respective arms. The observed hazard ratio for progression-free survival was 0.71 (95%CI: 0.41-1.21) and, after
    MeSH term(s) Adult ; Aged ; Aged, 80 and over ; Aminopterin/administration & dosage ; Aminopterin/analogs & derivatives ; Antibodies, Monoclonal, Humanized/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Cisplatin/administration & dosage ; Cytarabine/administration & dosage ; Deoxycytidine/administration & dosage ; Deoxycytidine/analogs & derivatives ; Dexamethasone/administration & dosage ; Drug Resistance, Neoplasm/drug effects ; Female ; Follow-Up Studies ; Humans ; International Agencies ; Leukemia-Lymphoma, Adult T-Cell/drug therapy ; Leukemia-Lymphoma, Adult T-Cell/pathology ; Male ; Middle Aged ; Neoplasm Recurrence, Local/drug therapy ; Neoplasm Recurrence, Local/pathology ; Oxaliplatin/administration & dosage ; Prognosis ; Retrospective Studies ; Salvage Therapy ; Survival Rate ; Young Adult
    Chemical Substances 10-propargyl-10-deazaaminopterin ; Antibodies, Monoclonal, Humanized ; Cytarabine (04079A1RDZ) ; Oxaliplatin (04ZR38536J) ; Deoxycytidine (0W860991D6) ; Dexamethasone (7S5I7G3JQL) ; gemcitabine (B76N6SBZ8R) ; Aminopterin (JYB41CTM2Q) ; Cisplatin (Q20Q21Q62J) ; mogamulizumab (YI437801BE)
    Language English
    Publishing date 2018-12-20
    Publishing country Italy
    Document type Clinical Trial, Phase II ; Comparative Study ; Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 2333-4
    ISSN 1592-8721 ; 0017-6567 ; 0390-6078
    ISSN (online) 1592-8721
    ISSN 0017-6567 ; 0390-6078
    DOI 10.3324/haematol.2018.205096
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.76: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma.

    Duvic, Madeleine / Pinter-Brown, Lauren C / Foss, Francine M / Sokol, Lubomir / Jorgensen, Jeffrey L / Challagundla, Pramoda / Dwyer, Karen M / Zhang, Xiaoping / Kurman, Michael R / Ballerini, Rocco / Liu, Li / Kim, Youn H

    Blood

    2015  Volume 125, Issue 12, Page(s) 1883–1889

    Abstract: This phase 1/2 study evaluated the efficacy of mogamulizumab, a defucosylated, humanized, anti-CC chemokine receptor 4 monoclonal antibody, in 41 pretreated patients with cutaneous T-cell lymphoma. No dose-limiting toxicity was observed and the maximum ... ...

    Abstract This phase 1/2 study evaluated the efficacy of mogamulizumab, a defucosylated, humanized, anti-CC chemokine receptor 4 monoclonal antibody, in 41 pretreated patients with cutaneous T-cell lymphoma. No dose-limiting toxicity was observed and the maximum tolerated dose was not reached in phase 1 after IV infusion of mogamulizumab (0.1, 0.3, and 1.0 mg/kg) once weekly for 4 weeks followed by a 2-week observation. In phase 2, patients were dosed with 1.0 mg/kg mogamulizumab according to the same schedule for the first course followed by infusion every 2 weeks during subsequent courses until disease progression. The most frequent treatment-emergent adverse events were nausea (31.0%), chills (23.8%), headache (21.4%), and infusion-related reaction (21.4%); the majority of events were grade 1/2. There were no significant hematologic effects. Among 38 evaluable patients, the overall response rate was 36.8%: 47.1% in Sézary syndrome (n = 17) and 28.6% in mycosis fungoides (n = 21). Eighteen of 19 (94.7%) patients with ≥B1 blood involvement had a response in blood, including 11 complete responses. Given the safety and efficacy of mogamulizumab, phase 3 investigation of mogamulizumab is warranted in cutaneous T-cell lymphoma patients. This trial was registered at www.clinicaltrials.gov as #NCT00888927.
    MeSH term(s) Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Humanized/administration & dosage ; Antibodies, Monoclonal, Humanized/therapeutic use ; Drug Administration Schedule ; Female ; Humans ; Lymphoma, T-Cell, Cutaneous/immunology ; Lymphoma, T-Cell, Cutaneous/therapy ; Male ; Maximum Tolerated Dose ; Middle Aged ; Mycosis Fungoides/immunology ; Mycosis Fungoides/therapy ; Prognosis ; Receptors, CCR4/immunology ; Sezary Syndrome/immunology ; Sezary Syndrome/therapy ; Treatment Outcome
    Chemical Substances Antibodies, Monoclonal, Humanized ; CCR4 protein, human ; Receptors, CCR4 ; mogamulizumab (YI437801BE)
    Language English
    Publishing date 2015-01-20
    Publishing country United States
    Document type Clinical Trial, Phase I ; Clinical Trial, Phase II ; Journal Article ; Multicenter Study ; Research Support, Non-U.S. Gov't
    ZDB-ID 80069-7
    ISSN 1528-0020 ; 0006-4971
    ISSN (online) 1528-0020
    ISSN 0006-4971
    DOI 10.1182/blood-2014-09-600924
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.140: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 364: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top